君实生物-U
(688180)
| 流通市值：342.58亿 | | | 总市值：458.93亿 |
| 流通股本：7.66亿 | | | 总股本：10.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,005,884,290.74 | 2,521,771,403.86 | 2,502,201,285.66 | 2,474,595,086.04 |
| 交易性金融资产 | 501,203,123.28 | 500,637,534.24 | 430,508,246.57 | 570,000,000 |
| 应收票据及应收账款 | 526,351,285.77 | 398,633,609.1 | 509,816,712.45 | 466,688,600.66 |
| 应收账款 | 526,351,285.77 | 398,633,609.1 | 509,816,712.45 | 466,688,600.66 |
| 预付款项 | 173,053,062.93 | 212,054,671.52 | 199,787,005.7 | 283,147,433.17 |
| 其他应收款合计 | 1,975,158.6 | 15,937,737.14 | 36,441,479.37 | 201,570,630.64 |
| 存货 | 556,901,925.59 | 589,122,166.6 | 584,470,922.86 | 567,442,634.42 |
| 一年内到期的非流动资产 | 1,305,207.71 | 2,261,036.15 | 2,187,306.15 | 4,746,758.42 |
| 其他流动资产 | 18,081,546.22 | 14,597,152.61 | 18,404,148.29 | 17,334,532.51 |
| 流动资产合计 | 4,784,755,600.84 | 4,255,015,311.22 | 4,283,817,107.05 | 4,585,525,675.86 |
| 非流动资产: | | | | |
| 长期股权投资 | 260,874,077.23 | 266,335,176.68 | 223,334,442.32 | 228,455,933.85 |
| 其他权益工具投资 | 46,475,734.55 | 52,280,196.65 | 62,565,091.14 | 43,570,437.54 |
| 其他非流动金融资产 | 1,122,479,258.81 | 999,078,246.37 | 940,504,669.94 | 825,298,707.07 |
| 固定资产 | 2,176,611,774.72 | 2,222,958,081.72 | 2,281,061,188.57 | 2,315,877,222.08 |
| 在建工程 | 1,987,782,840.03 | 1,885,992,451.78 | 1,858,563,731.17 | 1,693,261,195.29 |
| 使用权资产 | 98,447,476.77 | 95,378,567.84 | 55,598,802.53 | 50,607,736.54 |
| 无形资产 | 500,520,001.39 | 514,192,112.93 | 521,405,365.27 | 526,498,411.05 |
| 长期待摊费用 | 11,524,532.24 | 7,786,740.45 | 6,120,035.12 | 8,015,516.26 |
| 递延所得税资产 | 88,915,402.06 | 94,045,901.3 | 87,045,275.35 | 103,204,370.54 |
| 其他非流动资产 | 597,201,377.11 | 504,006,979.86 | 461,944,701.64 | 477,298,318.62 |
| 非流动资产合计 | 6,890,832,474.91 | 6,642,054,455.58 | 6,498,143,303.05 | 6,272,087,848.84 |
| 资产总计 | 11,675,588,075.75 | 10,897,069,766.8 | 10,781,960,410.1 | 10,857,613,524.7 |
| 流动负债: | | | | |
| 短期借款 | 937,737,265.71 | 943,930,283.74 | 678,106,154.4 | 631,656,782.41 |
| 应付票据及应付账款 | 1,033,217,220.49 | 1,058,927,840.6 | 1,232,683,826.19 | 984,192,219.84 |
| 应付账款 | 1,033,217,220.49 | 1,058,927,840.6 | 1,232,683,826.19 | 984,192,219.84 |
| 合同负债 | 18,608,832.83 | 118,269,684.33 | 8,165,732.53 | 162,981,528.94 |
| 应付职工薪酬 | 194,820,979.03 | 261,049,686.61 | 252,681,242.49 | 232,595,559.68 |
| 应交税费 | 25,963,985.01 | 23,798,638.46 | 39,575,276.61 | 35,574,827.08 |
| 其他应付款合计 | 50,071,630.89 | 26,763,439.43 | 35,768,048.63 | 36,180,635.11 |
| 一年内到期的非流动负债 | 708,312,706.38 | 611,915,244.73 | 246,789,095.44 | 213,788,135.65 |
| 其他流动负债 | 5,319.59 | 3,236.16 | 154,453.34 | 617.73 |
| 流动负债合计 | 2,968,737,939.93 | 3,044,658,054.06 | 2,493,923,829.63 | 2,296,970,306.44 |
| 非流动负债: | | | | |
| 长期借款 | 1,780,355,482.47 | 1,769,434,833.44 | 1,979,680,277.34 | 1,905,722,659.97 |
| 租赁负债 | 67,093,711.34 | 68,297,319.39 | 26,313,075.5 | 24,796,059.18 |
| 预计负债 | 7,784,303.65 | 7,930,986.18 | 9,566,615.01 | 17,624,701.47 |
| 递延收益 | 168,212,918.45 | 177,913,953.77 | 181,913,109.58 | 175,543,917.69 |
| 其他非流动负债 | 291,287,167.13 | 159,674,556.36 | 158,433,738.89 | 157,015,405.56 |
| 非流动负债合计 | 2,314,733,583.04 | 2,183,251,649.14 | 2,355,906,816.32 | 2,280,702,743.87 |
| 负债合计 | 5,283,471,522.97 | 5,227,909,703.2 | 4,849,830,645.95 | 4,577,673,050.31 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,026,689,871 | 985,689,871 | 985,689,871 | 985,689,871 |
| 资本公积 | 16,306,079,019.63 | 15,411,458,305.67 | 15,406,557,142.12 | 15,394,559,338.2 |
| 减:库存股 | 30,892,473.08 | 30,892,473.08 | 30,892,473.08 | 30,892,473.08 |
| 其他综合收益 | -175,853,159.8 | -170,141,648.92 | -159,937,004.34 | -190,011,657.5 |
| 未分配利润 | -10,753,688,797.85 | -10,575,869,426.04 | -10,340,993,199.41 | -9,986,835,322.23 |
| 归属于母公司股东权益合计 | 6,372,334,459.9 | 5,620,244,628.63 | 5,860,424,336.29 | 6,172,509,756.39 |
| 少数股东权益 | 19,782,092.88 | 48,915,434.97 | 71,705,427.86 | 107,430,718 |
| 股东权益合计 | 6,392,116,552.78 | 5,669,160,063.6 | 5,932,129,764.15 | 6,279,940,474.39 |
| 负债和股东权益合计 | 11,675,588,075.75 | 10,897,069,766.8 | 10,781,960,410.1 | 10,857,613,524.7 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-03-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |